Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Fiche du document
25 mars 2019
- doi: 10.1038/s41598-019-41532-3
- issn: 2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-019-41532-3
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30911084
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EB0D132F2B638
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Cancer therapy Cancer treatment Cancer--Therapy Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
M. Jermini et al., « Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. », Serveur académique Lausannois, ID : 10.1038/s41598-019-41532-3
Métriques
Partage / Export
Résumé
Complementary medicine (CM) is used by one third to one half of cancer patients throughout the world. The objective of this study was to describe the prevalence of CM use and the potential for interactions with cancer treatments in an academic oncology centre. A cross-sectional study was conducted among patients undergoing current cancer treatment. Among 132 included patients, 56% had used CM since their cancer diagnosis and 45% were using CM during cancer treatment at the time of the survey. The main CM used were green tea (35%), herbal tea (35%), homeopathy (27%), dietary supplements (27%), and herbal medicines (27%). A small majority of patients (58%) spontaneously mentioned the use of CM to their oncologist. Of 42 identified combinations of concomitant use of biologically based CM and anticancer agents among the study patients, the potential for pharmacokinetic interactions of clinical relevance was not expected in 17 combinations (40%), hypothetical and deemed unlikely in 23 (55%), and of probable low clinical relevance in 2 (5%). Considering the high prevalence of CM use, active enquiries should be made by healthcare professionals to detect symptoms that may relate to CM tolerance and effects or that suggest interactions between CM and cancer treatments.
